Ryan, Angela V., Wilson, Sue, Dr, Wakelam, Michael J. O., Warmington, Sally A., Dunn, Janet A., Hodgkin, Richard F. D., Martin, Ashley and Ismail, Tariq. (2006) A prospective study to assess the value of MMP-9 in improving the appropriateness of urgent referrals for colorectal cancer. BMC Cancer, Vol.6 (No.251). ISSN 1471-2407

Preview

PDF WRAP_Dunn_Prospective_study.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (238Kb)

Abstract

Background Bowel cancer is common and is a major cause of death. Most people with bowel symptoms who meet the criteria for urgent referral to secondary care will not be found to have bowel cancer, and some people who are found to have cancer will have been referred routinely rather than urgently. If general practitioners could better identify people who were likely to have bowel cancer or conditions that may lead to bowel cancer, the pressure on hospital clinics may be reduced, enabling these patients to be seen more quickly. Increased levels of an enzyme called matrix metalloproteinase 9 (MMP-9) have been found to be associated with such conditions, and this can be measured from a blood sample. This study aims to find out whether measuring MMP-9 levels could improve the appropriateness of urgent referrals for patients with bowel symptoms. Methods People aged 18 years or older referred to a colorectal clinic will be asked to complete a questionnaire about symptoms, recent injuries or chronic illnesses (these can increase the level of matrix metalloproteinases) and family history of bowel cancer. A blood sample will be taken from people who consent to take part to assess MMP-9 levels, and the results of examination at the clinic and/or investigations arising from the clinic visit will be collected from hospital records. The accuracy of MMP-9 will be assessed by comparing the MMP-9 level with the resulting diagnosis. The combination of factors (e.g. symptoms and MMP-9 level) that best predict a diagnosis of malignancy (invasive disease or polyps) will be determined. Discussion Although guidelines are in place to facilitate referrals to colorectal clinics, symptoms alone do not adequately distinguish people with malignancy from people with benign conditions. This study will establish whether MMP-9 could assist this process. If this were the case, measurement of MMP-9 levels could be used by general practitioners to assist in the identification of people who were most likely to have bowel cancer or conditions that may lead to bowel cancer, and who should, therefore, be referred most urgently to secondary care

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions:	Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Intestines -- Diseases, Cancer -- Diagnosis
Journal or Publication Title:	BMC Cancer
Publisher:	BioMed Central Ltd.
ISSN:	1471-2407
Date:	23 October 2006
Volume:	Vol.6
Number:	No.251
Identification Number:	10.1186/1471-2407-6-251
Status:	Peer Reviewed
Access rights to Published version:	Open Access
Funder:	University Hospital Birmingham Charities, Midlands Research Practices Consortium (MidReC), Wellcome Trust (London, England), Great Britain. Dept. of Health (DoH), NHS Research and Development
References:	1. National Cancer Intelligence Centre: Registrations of new cases of cancer diagnosed in England in 2000, by age group and sex. Rates per 100,000 population of new cases of cancer diagnosed in England in 2000, by age group and sex. [http:// www.statistics.gov.uk/STATBASE/ssdataset.asp?vInk=6989]. Accessed 21 January 2004 2. National Cancer Intelligence Centre: Deaths, 2001 registrations: Death by age, sex and underlying cause. [http://www.statis tics.gov.uk/StatBase/xsdataset.asp?vlnk=5670&Pos=1&Col Rank=1&Rank=272]. Accessed 22 January 2004 3. National Cancer Institute: Colon and rectum cancer (invasive). Survival rates, by race, sex, diagnosis, year, stage and age. [http://seer.cancer.gov/csr/1975_2003/]. Accessed 5th November 2006 4. Department of Health: Referral guidelines for suspected cancer. London 2000. 5. National Institute for Health and Clinical Excellence: Referral guidelines for Suspected Cancer. London 2005. 6. Flashman K, Leary DPO, Senapati A, Thompson MR: The Department of Health's "two week standard" for bowel cancer: is it working? Gut 2004, 53:387-391. 7. Parsons SL, Watson SA, Collins HM, Griffin NR, Clarke PA, Steele RJC: Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. British Journal of Cancer 1998, 78:1495-1502. 8. Heslin MJ, Yan J, Johnson MR, Weiss H, Diasio RB, Urist MM: Role of Matrix Metalloproteinases in Colorectal Carcinogenesis. Annals of Surgery 2001, 233:786-792. 9. Garbett EA, Reed MWR, Brown NJ: Proteolysis in human breast and colorectal cancer. British Journal of Cancer 1999, 81:287-293. 10. Ware JE, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Medical Care 1996, 34(3):220-233. 11. Spielberger CD, Gorsuch RL, Lushene RE: Manual for the State-Trait Anxiety Inventory California: Consulting Psychologists Press; 1970. 12. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G, for Veterans Affairs Cooperative Study Group: Use of colonoscopy to screen asymptomatic adults for colorectal cancer. New England Journal of Medicine 2000, 343:162-168. 13. Thiis-Evensen E, Hoff GS, Sauar J, Majak BM, Vatn MH: Flexible sigmoidoscopy or colonoscopy as a screening modality for colorectal adenomas in older age groups? Findings in a cohort of the normal population aged 63–72 years. Gut 1999, 45:834-839. 14. UK Flexible Sigmoidoscopy Screening Trial Investigators: Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002, 359:1291-1266.
URI:	http://wrap.warwick.ac.uk/id/eprint/558

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item